Development of learning-based predictive models for radiation-induced atrial fibrillation in non-small cell lung cancer patients by integrating patient-specific clinical, dosimetry, and diagnostic information

被引:1
作者
Yoo, Sang Kyun [1 ,2 ]
Kim, Kyung Hwan [1 ]
Noh, Jae Myoung [3 ]
Oh, Jaewon [4 ]
Yang, Gowoon [1 ,5 ]
Kim, Jihun [6 ]
Kim, Nalee [3 ]
Kim, Hojin [1 ]
Yoon, Hong In [1 ]
机构
[1] Yonsei Univ, Coll Med, Heavy Ion Therapy Res Inst, Dept Radiat Oncol,Yonsei Canc Ctr, 50-1 Yonsei Ro, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Med Phys & Biomed Engn Lab MPBEL, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[4] Yonsei Univ, Severance Cardiovasc Hosp, Dept Internal Med, Div Cardiol,Cardiovasc Res Inst,Coll Med, Seoul, South Korea
[5] Cha Univ, Ilsan Cha Hosp, Dept Radiat Oncol, Sch Med, Gyeonggi Do, South Korea
[6] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Radiat Oncol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Atrial fibrillation; Radiotherapy; Non-small cell lung cancer; Predictive Models; Machine learning; Deep learning; CARDIAC TOXICITY; RADIOTHERAPY; DISEASE; EVENTS; RISK;
D O I
10.1016/j.radonc.2024.110566
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Radiotherapy (RT) in non-small cell lung cancer (NSCLC) can induce cardiac adverse events, including atrial fibrillation (AF), despite advanced RT. This study integrates patient-specific information to develop learning-based models to predict the incidence of AF following NSCLC chemoradiotherapy (CRT) and evaluates these models using institutional and external datasets. Materials and methods: Institutional and external patient cohorts consisted of 321 and 187 NSCLC datasets who received definitive CRT, including 17 and 6 AF incidences, respectively. The network input had 159 features with clinical, dosimetry, and diagnostic. The class imbalance was mitigated by synthetic minority oversampling technique. To handle various types of input features, machine learning-based model adopted an intervention technique that chose one feature with the largest weight at each dosimetry sub-group in feature selection process, while deep learning-based model employed a hybrid architecture assigning different types of networks to corresponding input paths. Performance was assessed by area under the curve (AUC). The key features were investigated for the machine and deep learning-based models. Results: The hybrid deep learning model outperformed the machine learning-based algorithm in internal validation (AUC: 0.817 vs. 0.801) and produced more consistent performance in external validation (AUC: 0.806 vs. 0.776). Importantly, maximum dose to heart and sinoatrial node (SAN) were found to be the key features for both learning-based models in external and internal validations. Conclusions: The learning-based predictive models showed consistent prediction performance across internal and external cohorts, identifying maximum heart and SAN dose as key features for the incidence of AF.
引用
收藏
页数:8
相关论文
共 40 条
[1]   Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy [J].
Atkins, Katelyn M. ;
Bitterman, Danielle S. ;
Chaunzwa, Tafadzwa L. ;
Kozono, David E. ;
Baldini, Elizabeth H. ;
Aerts, Hugo J. W. L. ;
Tamarappoo, Balaji K. ;
Hoffmann, Udo ;
Nohria, Anju ;
Mak, Raymond H. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (05) :1473-1479
[2]   Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer [J].
Atkins, Katelyn M. ;
Chaunzwa, Tafadzwa L. ;
Lamba, Nayan ;
Bitterman, Danielle S. ;
Rawal, Bhupendra ;
Bredfeldt, Jeremy ;
Williams, Christopher L. ;
Kozono, David E. ;
Baldini, Elizabeth H. ;
Nohria, Anju ;
Hoffmann, Udo ;
Aerts, Hugo J. W. L. ;
Mak, Raymond H. .
JAMA ONCOLOGY, 2021, 7 (02) :206-219
[3]   Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer [J].
Atkins, Katelyn M. ;
Rawal, Bhupendra ;
Chaunzwa, Tafadzwa L. ;
Lamba, Nayan ;
Bitterman, Danielle S. ;
Williams, Christopher L. ;
Kozono, David E. ;
Baldini, Elizabeth H. ;
Chen, Aileen B. ;
Nguyen, Paul L. ;
D'Amico, Anthony V. ;
Nohria, Anju ;
Hoffmann, Udo ;
Aerts, Hugo J. W. L. ;
Mak, Raymond H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (23) :2976-2987
[4]   Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions [J].
Banfill, Kathryn ;
Giuliani, Meredith ;
Aznar, Marianne ;
Franks, Kevin ;
McWilliam, Alan ;
Schmitt, Matthias ;
Sun, Fei ;
Vozenin, Marie Catherine ;
Finn, Corinne Faivre .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) :216-227
[5]  
Bogart JA, 2021, Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC)
[6]   SMOTE: Synthetic minority over-sampling technique [J].
Chawla, Nitesh V. ;
Bowyer, Kevin W. ;
Hall, Lawrence O. ;
Kegelmeyer, W. Philip .
2002, American Association for Artificial Intelligence (16)
[7]   Acute coronary event (ACE) prediction following breast radiotherapy by features extracted from 3D CT, dose, and cardiac structures [J].
Choi, Byong Su ;
Yoo, Sang Kyun ;
Moon, Jinyoung ;
Chung, Seung Yeun ;
Oh, Jaewon ;
Baek, Stephen ;
Kim, Yusung ;
Chang, Jee Suk ;
Kim, Hojin ;
Kim, Jin Sung .
MEDICAL PHYSICS, 2023, 50 (10) :6409-6420
[8]   Risk of Cardiac Disease in Patients With Breast Cancer: Impact of Patient-Specific Factors and Individual Heart Dose From Three-Dimensional Radiation Therapy Planning [J].
Chung, Seung Yeun ;
Oh, Jaewon ;
Chang, Jee Suk ;
Shin, Jaeyong ;
Kim, Kyung Hwan ;
Chun, Kyeong-Hyeon ;
Keum, Ki Chang ;
Suh, Chang-Ok ;
Kang, Seok-Min ;
Kim, Yong Bae .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (02) :473-481
[9]  
Dosovitskiy A, 2021, Arxiv, DOI arXiv:2010.11929
[10]   Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J].
Faivre-Finn, Corinne ;
Snee, Michael ;
Ashcroft, Linda ;
Appel, Wiebke ;
Barlesi, Fabrice ;
Bhatnagar, Adityanarayan ;
Bezjak, Andrea ;
Cardenal, Felipe ;
Fournel, Pierre ;
Harden, Susan ;
Le Pechoux, Cecile ;
McMenemin, Rhona ;
Mohammed, Nazia ;
O'Brien, Mary ;
Pantarotto, Jason ;
Surmont, Veerle ;
Van Meerbeeck, Jan P. ;
Woll, Penella J. ;
Lorigan, Paul ;
Blackhall, Fiona .
LANCET ONCOLOGY, 2017, 18 (08) :1116-1125